Other
Increase (Decrease) in Accounts Receivable
Neurocrine Biosciences Increase (Decrease) in Accounts Receivable decreased by 38.5% to $81.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 120.6%, from $36.90M to $81.40M. Over 3 years (FY 2021 to FY 2024), Increase (Decrease) in Accounts Receivable shows an upward trend with a 13.8% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2015
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase often signals rising sales or slower collections, while a decrease suggests improved collection efficiency or declining sales volume.
Detailed definition
Measures the net change in amounts owed to the company by customers for goods or services delivered on credit. It reflec...
Peer comparison
A fundamental working capital metric used by all companies to assess cash conversion cycles.
Metric ID:
other_increase_decrease_in_accounts_receivableHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.70M | $5.30M | $21.70M | $78.00M | $15.50M | $22.20M | $46.50M | $41.70M | $0.00 | $30.40M | $21.40M | $11.30M | $17.60M | $12.90M | $0.00 | $36.90M | $79.70M | $132.30M | $81.40M |
| QoQ Change | — | -50.5% | +309.4% | +259.4% | -80.1% | +43.2% | +109.5% | -10.3% | -100.0% | — | -29.6% | -47.2% | +55.8% | -26.7% | -100.0% | — | +116.0% | +66.0% | -38.5% |
| YoY Change | — | — | — | — | +44.9% | +318.9% | +114.3% | -46.5% | -100.0% | +36.9% | -54.0% | -72.9% | — | -57.6% | -100.0% | +226.5% | +352.8% | +925.6% | +120.6% |
Range$0.00 – $132.30M
CAGR+57.0%
Avg YoY Growth+122.1%
Median YoY Growth+40.9%
Increase (Decrease) in Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's increase (decrease) in accounts receivable?
- Neurocrine Biosciences (NBIX) reported increase (decrease) in accounts receivable of $81.40M in Q1 2026.
- How has Neurocrine Biosciences's increase (decrease) in accounts receivable changed year-over-year?
- Neurocrine Biosciences's increase (decrease) in accounts receivable increased by 120.6% year-over-year, from $36.90M to $81.40M.
- What is the long-term trend for Neurocrine Biosciences's increase (decrease) in accounts receivable?
- Over 3 years (2021 to 2024), Neurocrine Biosciences's increase (decrease) in accounts receivable has grown at a 13.8% compound annual growth rate (CAGR), from $28.40M to $41.80M.
- What does increase (decrease) in accounts receivable mean?
- The change in the amount of money customers owe the company for past purchases.